By Hendra Lukman 
A groundbreaking advancement at Stanford Medicine promises to transform the landscape of stem cell transplantation, offering a less toxic and more accessible path for patients with rare genetic disorders. A Phase 1 clinical trial has demonstrated that a novel antibody therapy can effectively prepare patients for stem cell transplants, circumventing the need for debilitating chemotherapy and radiation. This innovative approach, detailed in a recent publication in Nature Medicine, has shown exceptional promise, particularly for individuals with Fanconi anemia, a condition that renders traditional transplant protocols exceptionally perilous.
A Paradigm Shift in Transplant Preparation
The core of this breakthrough lies in the development of an antibody, known as briquilimab, that targets CD117, a protein abundantly present on the surface of blood-forming stem cells. Historically, the critical pre-transplant step involves eliminating a patient’s own diseased or damaged stem cells to make way for healthy donor cells. This conditioning process has traditionally relied on high-dose chemotherapy, often including the genotoxic agent busulfan, and/or radiation. While effective, these methods carry significant risks of severe side effects, including secondary cancers, organ damage, and prolonged recovery periods, making them particularly challenging for vulnerable populations.
Stanford Medicine researchers have successfully demonstrated that briquilimab can selectively and safely deplete these target stem cells without inducing the widespread toxicity associated with conventional conditioning regimens. This offers a profound reduction in the immediate and long-term risks for transplant recipients.
"We were able to treat these really fragile patients with a new, innovative regimen that allowed us to reduce the toxicity of the stem cell transplant protocol," explained Agnieszka Czechowicz, MD, PhD, assistant professor of pediatrics and co-senior author of the study. "Specifically, we could eliminate the use of radiation and genotoxic chemotherapy called busulfan, with exceptional outcomes."
Addressing the Challenges of Fanconi Anemia
Fanconi anemia (FA) is a rare, autosomal recessive genetic disorder characterized by a defect in DNA repair mechanisms. This deficiency leads to progressive bone marrow failure, resulting in a critical shortage of essential blood cells: red blood cells, white blood cells, and platelets. Patients with FA often experience a cascade of health issues, including severe fatigue, stunted growth, increased susceptibility to infections, and a heightened risk of bleeding. Without intervention, FA is typically fatal by early adulthood due to bone marrow aplasia or the development of hematological malignancies like acute myeloid leukemia.
Stem cell transplantation is the only curative treatment for FA, offering the potential to restore normal blood cell production. However, the standard preparative regimens for FA patients have been fraught with peril. The very treatments designed to clear the way for new stem cells can exacerbate existing DNA damage and increase the risk of secondary cancers, a devastating paradox for individuals already predisposed to such complications. Approximately 80% of FA patients develop bone marrow failure by age 12, and nearly all face the prospect of secondary cancers by age 40 if treated with conventional methods.
"If they don’t get a transplant in time, Fanconi anemia patients’ bodies eventually will not make blood, so they die of bleeding or infections," stated Rajni Agarwal, MD, professor of pediatric stem cell transplantation and co-first author. "The reason I am so excited about this trial is that it is a novel approach to help these patients, who are very vulnerable."
The Journey from Bench to Bedside: A Decades-Long Endeavor
The success of this antibody therapy is not an overnight revelation but rather the culmination of over two decades of dedicated research at Stanford Medicine. The foundational work began in 2004 when Dr. Czechowicz, as an undergraduate, collaborated with Irving Weissman, MD, then director of Stanford’s Institute for Stem Cell Biology and Regenerative Medicine. Their early studies in mice provided crucial evidence that targeting CD117 with antibodies could effectively eliminate blood-forming stem cells without the need for harsh conditioning.
This initial discovery paved the way for identifying a human-compatible antibody. Through iterative research and development, the team refined the antibody and its application, eventually leading to the clinical trials that have now yielded such promising results. This journey exemplifies the slow, meticulous, yet ultimately rewarding process of translating fundamental scientific discoveries into life-saving clinical interventions.
Tackling the Donor Match Dilemma
Beyond mitigating the toxicity of conditioning regimens, the Stanford team also addressed another significant barrier to widespread stem cell transplantation: the challenge of finding compatible donors. Historically, a substantial proportion of patients, estimated to be up to 40%, were unable to proceed with transplants due to the scarcity of fully matched bone marrow donors.
To broaden the donor pool, the researchers implemented an innovative modification of donor bone marrow. This process involves enriching the donated marrow for CD34+ cells, which are the critical blood-forming stem cells, while simultaneously depleting immune cells known as alpha/beta T-cells. The removal of these T-cells is crucial for preventing graft-versus-host disease (GVHD), a potentially life-threatening complication where the donor’s immune cells attack the recipient’s body. This sophisticated manipulation of donor marrow, pioneered by Alice Bertaina, MD, PhD, enables safe transplants from half-matched donors, including parents, thereby dramatically increasing the number of patients who can access this life-saving therapy.
"We are expanding the donors for stem cell transplantation in a major way, so every patient who needs a transplant can get one," Dr. Agarwal emphasized.
A Child’s Triumph: Ryder’s Story of Recovery
The transformative impact of this new therapy is vividly illustrated by the story of Ryder Baker, an 11-year-old from Seguin, Texas, who was the first patient to receive the treatment. Undergoing the transplant at Lucile Packard Children’s Hospital Stanford in early 2022, Ryder’s journey represents a beacon of hope for countless others.
Prior to the transplant, Ryder’s life was significantly impacted by Fanconi anemia. His mother, Andrea Reiley, described him as constantly fatigued and lacking stamina. "He was so tired, he didn’t have stamina. It’s completely different now," she shared, noting that his condition no longer hinders him as it once did.
Today, Ryder is thriving, a testament to the success of the novel treatment. He has regained his energy, successfully completed fifth grade, participates actively in sports, and was even recognized with an "Up and Coming Player" award for his school soccer team. His recovery signifies not just a medical success but a profound restoration of childhood vitality and potential.
"It was heartbreaking to see him go through things like that — I’d rather go through it than my child," Ms. Reiley reflected on the challenges of his illness. "I felt the heartbreak for him, and now he doesn’t have to." She also expressed pride in Ryder’s role as one of the pioneering patients, understanding that his experience will pave the way for others.
Clinical Trial Details and Promising Outcomes
The Phase 1 clinical trial involved three young patients, all under the age of 10, each with distinct genetic variations of Fanconi anemia. The protocol was remarkably streamlined: each child received a single intravenous dose of briquilimab 12 days prior to their transplant. Crucially, this was followed by standard immunosuppressive medications but deliberately excluded busulfan and radiation.
The donated stem cells were sourced from a parent and underwent meticulous processing to remove the problematic alpha/beta T-cells. Within a mere two weeks of the transplant, the new stem cells had successfully engrafted in the patients’ bone marrow. None of the participants experienced graft rejection. By one month post-transplant, the donor cells had almost entirely replaced the patients’ own cells, a significant achievement.
The research team’s initial target was a modest 1% presence of donor cells. However, the results far exceeded expectations. Two years later, all three children exhibited nearly 100% donor cell chimerism, indicating a complete and robust restoration of healthy blood-forming stem cell function.
"We’ve been surprised by how well it’s worked," Dr. Czechowicz commented. "We were optimistic that we would get here, but you never know when you’re trying a new regimen." This level of success underscores the efficacy and safety of the antibody-based conditioning approach.
Future Implications and Broader Applications
The implications of this research extend far beyond Fanconi anemia. Researchers are optimistic that this antibody-based conditioning strategy can be adapted for patients with a wide spectrum of inherited diseases that necessitate stem cell transplantation.
"Bone marrow or stem cell transplants are most commonly used in blood cancers, in which the bone marrow is full of malignant cells and patients have no other options," Dr. Czechowicz explained. "But as we’re making these transplants better and safer, we can expand them to more patients including those with many different diseases."
The team is already initiating a Phase 2 clinical trial involving a larger cohort of children with Fanconi anemia. Furthermore, they plan to investigate the applicability of this antibody approach to other rare bone marrow failure disorders, such as Diamond-Blackfan anemia.
Even for patients with blood cancers, where chemotherapy and radiation are often essential for eradicating malignant cells, this new therapy may offer benefits. Researchers are exploring whether the antibody can be used in conjunction with reduced-intensity chemotherapy or radiation for elderly cancer patients who may not tolerate conventional high-dose conditioning.
"That population is often at a disadvantage," Dr. Agarwal noted. "It may provide us with a way to treat them with less intensity so it’s possible for them to get a transplant."
The ongoing development of next-generation antibody-based treatments by the Stanford team aims to further refine these outcomes and enhance the efficacy of transplants for Fanconi anemia and similar conditions.
Collaboration and Support Fueling Innovation
This pioneering research was a collaborative effort involving numerous institutions and individuals. Key contributors include Agnieszka Czechowicz, MD, PhD; Rajni Agarwal, MD; Alice Bertaina, MD, PhD; and Matthew Porteus, MD, PhD, alongside researchers from the University of California, San Francisco; Kaiser Permanente Bernard J. Tyson School of Medicine; St. Jude Children’s Research Hospital; Memorial Sloan Kettering Cancer Center; and Jasper Therapeutics Inc.
The project received vital financial support from anonymous donors, the California Institute of Regenerative Medicine, and the Fanconi Cancer Foundation. Jasper Therapeutics provided the critical antibody, briquilimab, and the Stanford Clinical Trial Program was instrumental in facilitating the study’s implementation. This broad base of support highlights the widespread recognition of the potential of this innovative approach.
The successful completion of this Phase 1 trial marks a significant milestone, offering a tangible and less toxic alternative to traditional transplant preparation. As Dr. Agarwal observed, "When I counsel families, their eyes start to shine as they think, ‘OK, we can avoid the radiation and chemo toxicity.’" This new era in stem cell transplantation holds the promise of not only improving survival rates but also dramatically enhancing the quality of life for patients facing devastating diseases.
